Simple and Accessible
Stratford Management WHAT WE DO
Why Choose Us
We have a reputation for hiring and fostering the industry’s top talent to support our company mission. Our teams include people from a variety of professional backgrounds with many having 20+ year careers in the industry.
At Stratford Management, people are at the heart of everything we do. Our management team takes great pride in inspiring a positive work environment, encouraging team collaboration and giving every individual the proper balance of support and autonomy to learn the necessary skills to do the best for our clientele.
We firmly believe that by giving employees all needed support, they will inherently become strong performers in the marketplace. We invest in leading products and services for our employees and their clients.
A firm advocate of equal opportunity, Stratford Management employs people from all backgrounds to work with our international client base. Our staff are trained to understand the nuances of different cultures, ensuring all clients are treated with respect.
More than 25 Years
Informed Investment Decisions
With Stratford Management, you receive comprehensive support to ensure the best possible results for your investment strategy. Your personal Stratford Management advisor will base decisions on the investment plan tailored to meet your specific needs. Long-term relationships built on trust are the foundation of our financial services.
We Are Hiring
We are always on the look out for motivated, dedicated and talented colleagues. We offer an inspiring, international environment and a wide range of opportunities. The long-term outlook we take with our clients extends to our employees. Motivated and engaged people are our greatest strength and key to our success.
Our reputation precedes us. Here is what clients are saying.
“Thank you for everything. In addition to the wisdom and helpful financial guidance, the time you take explaining things give me a better understanding of what’s happening in the world.”
“At Stratford, they take time to really listen and understand your life experience before offering guidance and feedback. They’re careful, methodical and systematic in their approach. Common sense is not so common.”
“My wife and I enjoy our annual portfolio review. We feel confident about where we’re headed. We understand the rationale behind all of our investments. We feel secure knowing you’re watching over our portfolio.”
Request a Call Back.
News Updates 24/7
– Karma’s first ever all-electric variant to debut in 2021 – New family of sedans to wear the GS badge with updated technology and powertrain options – Reservation site created for pre-orders IRVINE, California, Sept. 22, 2020 /PRNewswire/ — Karma Automotive today announced it will be introducing a new name for a family of vehicles in 2021 called the GS Series. The lineup will include updated electrification options, technological advancements and Karma’s first-ever battery electric (BEV) luxury sedan. To facilitate orders, Karma created a new pre-reservation order site which is now live at https://www.karmaautomotive.com/reserve. For a fully-refundable $100 deposit, interested individuals can reserve a place in line. The GS lineup will retain the same exotic design of the Revero® to continue with the brand’s legacy but will include technological advancements and a price point that will help bring new customers into the brand. “We are pleased to announce that Karma will now offer our first all-electric vehicle next year as part of the GS series,” said Dr. Lance Zhou, Karma’s CEO. “Cost reductions in the BOM, streamlining our supply chain and standardized production methods also allowed for a new, more attainable pricing structure for the GS lineup allowing for higher market penetration,September 22, 2020
STOCKHOLM, Sept. 22, 2020 /PRNewswire/ — In the current situation with Covid-19, consumers and brands alike seek new solutions. Concerns over viruses begin even at the shopping stage, where markets like Italy require disinfection of garments before they are sold to consumers. YKK has developed a line of zippers with tape treated with Polygiene’s ViralOff®, so these parts are essentially self-cleaning. Always faithful to the philosophy of the “Cycle of Goodness”, which places corporate responsibility, transparency and respect for others at the center of every business decision, YKK is now focused on what even a detail such as the zipper can offer. The chemical components are eco-sustainable and ViralOff encourages a reduction in the frequency of washing of the garments, prolonging their life cycle and reducing the consumption of energy, water and chemical additives. “This zipper is the protagonist of the motto that completes the YKK logo `Little Parts, Big Difference’ and is the motto which the Group has worked by for more than 80 years”, says Enrico Degara, CSO (Chief Sustainability Officer) of YKK ITALIA s.p.a.”It may be a small detail, but an important one. While we never make any claims beyond protecting the product itself, it goes withoutSeptember 22, 2020
'Hooligan logic': Chinese state media hardens stance on TikTok deal, casts doubt over Beijing's approval
China and U.S. flags are seen near a TikTok logo in this illustration picture taken July 16, 2020.
Florence Lo | Reuters
Chinese state media has accused the U.S. of “hooligan logic” in its push for certain conditions in the TikTok deal and cast doubt over whether Beijing will approve the terms.
State-backed Global Times appears to have changed its stance toward the deal after more confusion over the terms of the agreement in which a new U.S.-based company, called TikTok Global, will be set up with U.S. giants Walmart and Oracle taking minority stakes.
The publication, often seen as being close to Beijing’s thinking, called the deal “unfair” on Monday and accused Washington of “bullying” and “hooligan logic” because of the specific terms of the deal.
The Chinese tabloid completely changed its tune just one day after saying it expects Beijing to approve the “reasonable” deal.
Confusion currently reigns and things are getting messier.
On Saturday, President Donald Trump gave an in-principle approval to the deal which would see Oracle become TikTok’s cloud provider, hosting and processing U.S. user data. TikTok would avoid being shutdown in the U.S.
On Sunday, Global Times published an opinion piece in which it called the deal “reasonable,” saying ByteDance had avoided the worst-case scenario of a TikTok shutdown or full sale. The tabloid added that the Chinese government was likely to approve the deal.
On Monday morning China time, TikTok’s parent company ByteDance released a statement in Chinese in which it said it was clearing up rumors around the deal. ByteDance said it would own an 80% stake in TikTok Global and would not transfer any algorithms or technology to Oracle. Instead, Oracle could inspect the source code to ensure it addresses Washington’s national security concerns.
Then on Monday morning in the U.S., Trump said on Fox News that the Chinese wouldn’t have anything to do with TikTok after the deal was sealed, and that Oracle and Walmart would have “total control” over the app, which is actually not the case.
Oracle’s Executive Vice President Ken Glueck released a statement to CNBC shortly after Trump’s remarks that said Americans will have a “majority” of control over TikTok Global. He also said ByteDance will “have no ownership” over the new entity.
From ‘reasonable’ to ‘robbery’: Global Time changes its view
The latest comments from Trump and Oracle appear to have changed the Global Times’s view on things. In an opinion piece published late Monday, the state-backed tabloid ran the headline: “Say ‘No!’ to US robbery of TikTok.”
“It caters to the unreasonable demands of Washington. It’s hard for us to believe that Beijing will approve such an agreement,” the Monday op-ed read.
In the article, they took issue with a few of the terms of the deal. One was that Americans would make up four out of five of the board seats of TiKTok Global, while ByteDance’s CEO and founder Zhang Yiming will take the remaining one.
Another issue was the fact that Oracle would be able to inspect TikTok’s source code. The Chinese tabloid claimed that “TikTok and Douyin should have the same source code, this means the US can get to know the operations of Douyin, the Chinese version of TikTok.”
Douyin is the Chinese version of TikTok, and is operated only in China by ByteDance. It’s not clear whether the source code for both Douyin and TikTok is the same, or whether Oracle would be able to get to know Douyin’s operations as a result.
The Global Times also claims that TikTok Global will control the business of TikTok around the world and alleged that it will block users from the Chinese mainland from accessing it. It is still not clear if TikTok Global would block Chinese internet users from accessing the app.
ByteDance did not respond to a request for comment on the latest developments and the claims made by the Global Times when contacted by CNBC.
Oracle was not immediately available for comment when contacted by CNBC.September 22, 2020
(RTTNews) – Today’s Daily Dose brings you news about ARCA biopharma’s progress related to its COVID-19 drug candidate, ADC Therapeutics’ submission of Loncastuximab tesirine BLA, BridgeBio’s initiation of ADH1 study, ERYTECH Pharma’s anticipated milestones, and the progress in Lipocine’s NASH trial. Read on… 1. ARCA biopharma Joins battle Against COVID-19 ARCA biopharma Inc. (ABIO) has submitted an Investigational New Drug application with the FDA, seeking clearance to initiate a phase IIb/III trial of AB201 for the treatment of patients hospitalized with COVID-19. AB201 is a potent, selective inhibitor of tissue factor (TF), which has been identified as playing a central role in the inflammatory response to viral infections. If cleared, the company anticipates initiating the phase IIb portion of the trial as early as the fourth quarter of this year. ABIO closed Monday’s trading at $4.63, down 10.62%. In after-hours, the stock was up 2.59% at $4.75. 2. ADC Therapeutics Submits Lonca BLA ADC Therapeutics SA (ADCT) has submitted a Biologics License Application to the FDA for Loncastuximab tesirine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. Loncastuximab Tesirine or Lonca is an antibody-drug conjugate composed of a humanized monoclonal antibody that binds to humanSeptember 22, 2020